Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EPS (Weighted Average and Diluted) (2016 - 2018)

Historic EPS (Weighted Average and Diluted) for UroGen Pharma (URGN) over the last 2 years, with Q4 2017 value amounting to -$0.74.

  • UroGen Pharma's EPS (Weighted Average and Diluted) fell 14746.43% to -$0.74 in Q4 2017 from the same period last year, while for Dec 2017 it was -$0.61, marking a year-over-year change of. This contributed to the annual value of -$1.47 for FY2017, which is 52781.96% down from last year.
  • Latest data reveals that UroGen Pharma reported EPS (Weighted Average and Diluted) of -$0.74 as of Q4 2017, which was down 14746.43% from $1.56 recorded in Q4 2016.
  • UroGen Pharma's EPS (Weighted Average and Diluted)'s 5-year high stood at $1.56 during Q4 2016, with a 5-year trough of -$0.74 in Q4 2017.